Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases
Joint Authors
Wannaprasert, Jerasak
Leelawat, Surang
Narong, Siriluck
Leelawat, Kawin
Source
International Journal of Hepatology
Issue
Vol. 2011, Issue 2011 (31 Dec. 2011), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2010-08-31
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Aim.
To determine whether the serum level of NGAL can discriminate cholangiocarcinoma from benign biliary tract disease in patients.
Methods.
This study was performed according to a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design.
A total of 50 cholangiocarcinoma and 50 benign biliary tract disease cases were randomly selected from a cohort of consecutive cases of biliary tract diseases.
Their sera were measured for the levels of NGAL and the widely used serum cholangiocarcinoma marker, carbohydrate antigen 19-9 (CA19-9).
Results.
The serum CA19-9 and NGAL levels were significantly elevated in cholangiocarcinoma patients (CA19-9: P<.001, NGAL: P<.001).
The area under the curve (AUC) of a receiver operating characteristic (ROC) curve analysis for the diagnosis of cholangiocarcinoma of CA19-9 and NGAL was 0.81 and 0.79, respectively.
Conclusion.
The diagnostic accuracy of serum NGAL and CA19-9 makes them good candidates for use as biomarkers to discriminate cholangiocarcinoma patients from benign biliary tract disease patients.
American Psychological Association (APA)
Leelawat, Kawin& Narong, Siriluck& Wannaprasert, Jerasak& Leelawat, Surang. 2010. Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases. International Journal of Hepatology،Vol. 2011, no. 2011, pp.1-6.
https://search.emarefa.net/detail/BIM-505200
Modern Language Association (MLA)
Leelawat, Kawin…[et al.]. Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases. International Journal of Hepatology No. 2011 (2011), pp.1-6.
https://search.emarefa.net/detail/BIM-505200
American Medical Association (AMA)
Leelawat, Kawin& Narong, Siriluck& Wannaprasert, Jerasak& Leelawat, Surang. Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases. International Journal of Hepatology. 2010. Vol. 2011, no. 2011, pp.1-6.
https://search.emarefa.net/detail/BIM-505200
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-505200